|
|
Biotechnology and Pharmaceuticals - "Go add url"
Directory /
|
|
|
|
|
|
| Biotechnology and Pharmaceuticals
|
Latest world news for Biotechnology and Pharmaceuticals
|
Vertex Pharmaceuticals Announces Webcast of its Presentation at the 27th Annual J.P. Morgan Healthcare Conference (Centre Daily Times)
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 27 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2009 at 1:30 p.m. PST (4:30 p.m. EST).
Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor Of CK2 (Medical News Today)
Cylene Pharmaceuticals announced that it has initiated a Phase I clinical trial of its oral CK2 protein kinase inhibitor, CX-4945, in patients with advanced solid tumors, Castleman's disease, or multiple myeloma. The primary endpoints of the oral dose escalating trial are determination of safety, tolerance and PK properties of CX-4945 and to select the appropriate dose for Phase II trials.
CyDex Pharmaceuticals Announces CAPTISOL® Technology Used In Recently Approved Cosolvent-Free Formulation Of ... (PharmaceuticalOnline)
CyDex Pharmaceuticals, Inc. recently announced that Prism Pharmaceuticals' NEXTERONE®, which recently received new drug application (NDA) approval from the U.S. Food and Drug Administration (FDA), is based on the patent-protected CyDex CAPTISOL® technology platform.
Provectus Pharmaceuticals Updates Shareholders on 2008 Accomplishments (Centre Daily Times)
Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, reports on its clinical and corporate accomplishments for 2008 in a letter to shareholders from Craig Dees, Ph.D., CEO of Provectus.
Vertex Pharmaceuticals Announces Webcast of its Presentation at the 27th Annual J.P. Morgan Healthcare Conference (Business Wire via Yahoo! Finance)
CAMBRIDGE, Mass.----Vertex Pharmaceuticals Incorporated today announced that it will webcast its corporate presentation at the 27th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2009 at 1:30 p.m.
|
|
|
|
